» Articles » PMID: 22733780

Mapping the HLA-DO/HLA-DM Complex by FRET and Mutagenesis

Overview
Specialty Science
Date 2012 Jun 27
PMID 22733780
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

HLA-DO (DO) is a nonclassic class II heterodimer that inhibits the action of the class II peptide exchange catalyst, HLA-DM (DM), and influences DM localization within late endosomes and exosomes. In addition, DM acts as a chaperone for DO and is required for its egress from the endoplasmic reticulum (ER). These reciprocal functions are based on direct DO/DM binding, but the topology of DO/DM complexes is not known, in part, because of technical limitations stemming from DO instability. We generated two variants of recombinant soluble DO with increased stability [zippered DOαP11A (szDOv) and chimeric sDO-Fc] and confirmed their conformational integrity and ability to inhibit DM. Notably, we found that our constructs, as well as wild-type sDO, are inhibitory in the full pH range where DM is active (4.7 to ∼6.0). To probe the nature of DO/DM complexes, we used intermolecular fluorescence resonance energy transfer (FRET) and mutagenesis and identified a lateral surface spanning the α1 and α2 domains of szDO as the apparent binding site for sDM. We also analyzed several sDM mutants for binding to szDOv and susceptibility to DO inhibition. Results of these assays identified a region of DM important for interaction with DO. Collectively, our data define a putative binding surface and an overall orientation of the szDOv/sDM complex and have implications for the mechanism of DO inhibition of DM.

Citing Articles

Deficiency in non-classical major histocompatibility class II-like molecule, H2-O confers protection against Staphylococcus aureus in mice.

Cullum E, Perez-Betancourt Y, Shi M, Gkika E, Schneewind O, Missiakas D PLoS Pathog. 2024; 20(6):e1012306.

PMID: 38843309 PMC: 11185455. DOI: 10.1371/journal.ppat.1012306.


Molecular Determinants Regulating the Plasticity of the MHC Class II Immunopeptidome.

Santambrogio L Front Immunol. 2022; 13:878271.

PMID: 35651601 PMC: 9148998. DOI: 10.3389/fimmu.2022.878271.


Tuning DO:DM Ratios Modulates MHC Class II Immunopeptidomes.

Olsson N, Jiang W, Adler L, Mellins E, Elias J Mol Cell Proteomics. 2022; 21(3):100204.

PMID: 35085787 PMC: 10329146. DOI: 10.1016/j.mcpro.2022.100204.


Crosstalk between RNA-Binding Proteins and Immune Microenvironment Revealed Two RBP Regulatory Patterns with Distinct Immunophenotypes in Periodontitis.

Xing L, Meng G, Chen T, Zhang X, Bai D, Xu H J Immunol Res. 2021; 2021:5588429.

PMID: 34285922 PMC: 8275429. DOI: 10.1155/2021/5588429.


How Does B Cell Antigen Presentation Affect Memory CD4 T Cell Differentiation and Longevity?.

Welsh R, Song N, Sadegh-Nasseri S Front Immunol. 2021; 12:677036.

PMID: 34177919 PMC: 8224923. DOI: 10.3389/fimmu.2021.677036.


References
1.
Roche P, Cresswell P . Proteolysis of the class II-associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules. Proc Natl Acad Sci U S A. 1991; 88(8):3150-4. PMC: 51403. DOI: 10.1073/pnas.88.8.3150. View

2.
Gruber H, Hahn C, Kada G, Riener C, Harms G, Ahrer W . Anomalous fluorescence enhancement of Cy3 and cy3.5 versus anomalous fluorescence loss of Cy5 and Cy7 upon covalent linking to IgG and noncovalent binding to avidin. Bioconjug Chem. 2000; 11(5):696-704. DOI: 10.1021/bc000015m. View

3.
Denzin L, Hammond C, Cresswell P . HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules. J Exp Med. 1996; 184(6):2153-65. PMC: 2196380. DOI: 10.1084/jem.184.6.2153. View

4.
Sloan V, Cameron P, Porter G, Gammon M, Amaya M, Mellins E . Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature. 1995; 375(6534):802-6. DOI: 10.1038/375802a0. View

5.
Denzin L, Cresswell P . HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading. Cell. 1995; 82(1):155-65. DOI: 10.1016/0092-8674(95)90061-6. View